The role of tacrolimus in renal transplantation

Lyndsey J. Bowman, Daniel C. Brennan

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


Tacrolimus gained FDA approval for use in liver transplantation in 1994 and, approximately 3 years later, was approved for the prevention of acute rejection in kidney transplantation. Over the last decade tacrolimus has become the calcineurin inhibitor of choice for the prevention of rejection in renal transplantation. The objective of this study was to provide a review and update of the literature on the use of tacrolimus in renal transplantation. Numerous clinical trials have shown tacrolimus to be superior to cyclosporine in the prevention of acute rejection and recent trials have demonstrated superiority of tacrolimus over cyclosporine in terms of allograft survival. Post-transplant diabetes remains more common with tacrolimus than cyclosporine, despite lower doses of both tacrolimus and corticosteroids. A novel once-daily dosage form of tacrolimus has recently been developed and is approved for use in Europe. Tacrolimus remains an important immuno-suppressant for the prevention of acute rejection. The prolonged-release formulation may improve compliance and possibly long-term outcomes.

Original languageEnglish (US)
Pages (from-to)635-643
Number of pages9
JournalExpert opinion on pharmacotherapy
Issue number4
StatePublished - Mar 2008
Externally publishedYes


  • Calcineurin inhibitor
  • Kidney transplantation
  • Prograf
  • Renal transplantation
  • Tacrolimus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The role of tacrolimus in renal transplantation'. Together they form a unique fingerprint.

Cite this